The Patients' Access to Treatments Act of 2015 was introduced earlier this year to rein in the high cost-sharing requirements for specialty drugs.
Earlier this year, US Representatives David McKinley (R-WV) and Lois Capps (D-CA), co-sponsored the Patients' Access to Treatments Act of 2015 that is applicable to health plans that have formulariers or a tiered cost-sharing structure. The objective: reduce the increasing cost-sharing requirements for patients imposed by the preferred versus non-preferred tiering of some of the prescription medications.
The American Society of Clinical Oncology has now announced that it endorses the Act that will shield patients from mounting co-payment burdens of specialty formulations.
“The imposition of high cost-sharing requirements is increasingly becoming a barrier for cancer patients,” wrote ASCO President Julie Vose, MD, MBA, FASCO. “In some cases, cancer patients are simply unable to afford the appropriate treatment, placing them at risk of a less successful outcome, or a more debilitating treatment regimen.”
Trump Administration’s Message to Supreme Court Puts New Wrinkle in Braidwood Case
February 21st 2025The Trump administration argues that HHS Secretary Robert F. Kennedy Jr can overrule the US Preventive Services Task Force to determine the preventive services covered under the Affordable Care Act.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Insurance Payer Is Associated With Length of Stay After Traumatic Brain Injury
February 21st 2025Among hospitalized patients with traumatic brain injury, Medicaid fee-for-service was associated with longer hospital stays than private insurance and Medicaid managed care organizations.
Read More